Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 155

1.

Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.

Merelli B, Massi D, Cattaneo L, MandalĂ  M.

Crit Rev Oncol Hematol. 2014 Jan;89(1):140-65. doi: 10.1016/j.critrevonc.2013.08.002. Epub 2013 Aug 28. Review.

PMID:
24029602
[PubMed - indexed for MEDLINE]
2.

A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.

Barsoum IB, Smallwood CA, Siemens DR, Graham CH.

Cancer Res. 2014 Feb 1;74(3):665-74. doi: 10.1158/0008-5472.CAN-13-0992. Epub 2013 Dec 13.

PMID:
24336068
[PubMed - indexed for MEDLINE]
3.

Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer.

Maine CJ, Aziz NH, Chatterjee J, Hayford C, Brewig N, Whilding L, George AJ, Ghaem-Maghami S.

Cancer Immunol Immunother. 2014 Mar;63(3):215-24. doi: 10.1007/s00262-013-1503-x. Epub 2013 Dec 3.

PMID:
24297569
[PubMed - indexed for MEDLINE]
4.

Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.

Hamid O, Carvajal RD.

Expert Opin Biol Ther. 2013 Jun;13(6):847-61. doi: 10.1517/14712598.2013.770836. Epub 2013 Feb 19. Review.

PMID:
23421934
[PubMed - indexed for MEDLINE]
5.

PD-1 as a potential target in cancer therapy.

McDermott DF, Atkins MB.

Cancer Med. 2013 Oct;2(5):662-73. doi: 10.1002/cam4.106. Epub 2013 Jul 21. Review.

PMID:
24403232
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, Wilkerson MD, Fecci PE, Butaney M, Reibel JB, Soucheray M, Cohoon TJ, Janne PA, Meyerson M, Hayes DN, Shapiro GI, Shimamura T, Sholl LM, Rodig SJ, Freeman GJ, Hammerman PS, Dranoff G, Wong KK.

Cancer Discov. 2013 Dec;3(12):1355-63. doi: 10.1158/2159-8290.CD-13-0310. Epub 2013 Sep 27.

PMID:
24078774
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.

Sznol M, Chen L.

Clin Cancer Res. 2013 Mar 1;19(5):1021-34. doi: 10.1158/1078-0432.CCR-12-2063.

PMID:
23460533
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor.

Prosser ME, Brown CE, Shami AF, Forman SJ, Jensen MC.

Mol Immunol. 2012 Jul;51(3-4):263-72. doi: 10.1016/j.molimm.2012.03.023. Epub 2012 Apr 11.

PMID:
22503210
[PubMed - indexed for MEDLINE]
9.

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M.

N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.

PMID:
22658127
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

[Effect of soluble PD-L1 released by lung cancer cells in regulating the function of T lymphocytes].

Shi MH, Xing YF, Zhang ZL, Huang JA, Chen YJ.

Zhonghua Zhong Liu Za Zhi. 2013 Feb;35(2):85-8. doi: 10.3760/cma.j.issn.0253-3766.2013.02.002. Chinese.

PMID:
23714659
[PubMed - indexed for MEDLINE]
11.

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM.

N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2.

PMID:
22658128
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.

Ott PA, Hodi FS, Robert C.

Clin Cancer Res. 2013 Oct 1;19(19):5300-9. doi: 10.1158/1078-0432.CCR-13-0143. Review.

PMID:
24089443
[PubMed - indexed for MEDLINE]
Free Article
13.

The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.

Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi FS.

Clin Cancer Res. 2013 Feb 1;19(3):598-609. doi: 10.1158/1078-0432.CCR-12-2731. Epub 2012 Oct 24.

PMID:
23095323
[PubMed - indexed for MEDLINE]
Free Article
14.

Dynamic interplay of oncogenes and T cells induces PD-L1 in the tumor microenvironment.

Rech AJ, Vonderheide RH.

Cancer Discov. 2013 Dec;3(12):1330-2. doi: 10.1158/2159-8290.CD-13-0775.

PMID:
24327693
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma.

Kearl TJ, Jing W, Gershan JA, Johnson BD.

J Immunol. 2013 Jun 1;190(11):5620-8. doi: 10.4049/jimmunol.1202005. Epub 2013 Apr 24.

PMID:
23616570
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

[Targeting the PD-1/PD-L1 immune checkpoint signal - a new treatment strategy for cancer].

Hamanishi J, Konishi I.

Gan To Kagaku Ryoho. 2014 Sep;41(9):1071-6. Japanese.

PMID:
25248890
[PubMed - indexed for MEDLINE]
17.

Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.

Chen DS, Irving BA, Hodi FS.

Clin Cancer Res. 2012 Dec 15;18(24):6580-7. doi: 10.1158/1078-0432.CCR-12-1362. Epub 2012 Oct 19.

PMID:
23087408
[PubMed - indexed for MEDLINE]
Free Article
18.

RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells.

Borkner L, Kaiser A, van de Kasteele W, Andreesen R, Mackensen A, Haanen JB, Schumacher TN, Blank C.

Cancer Immunol Immunother. 2010 Aug;59(8):1173-83. doi: 10.1007/s00262-010-0842-0. Epub 2010 Mar 27.

PMID:
20349059
[PubMed - indexed for MEDLINE]
19.

Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.

Simeone E, Ascierto PA.

J Immunotoxicol. 2012 Jul-Sep;9(3):241-7. doi: 10.3109/1547691X.2012.678021. Epub 2012 Apr 23. Review.

PMID:
22524673
[PubMed - indexed for MEDLINE]
20.

PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL).

Berghoff AS, Ricken G, Widhalm G, Rajky O, Hainfellner JA, Birner P, Raderer M, Preusser M.

Clin Neuropathol. 2014 Jan-Feb;33(1):42-9.

PMID:
24359606
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk